• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Fresenius Medical Care Extracorporeal Alliance Awarded Joint Commission Certification

Posted on: Thursday, 6 April 2006, 12:00 CDT

Fresenius Medical Care Extracorporeal Alliance (FMCEA), a division of Fresenius Medical Care North America, which is a wholly owned subsidiary of Fresenius Medical Care AG & Co. KGaA (FWB: FME, FME3) (NYSE: FMS, FMS-p), has achieved the Gold Seal of Approval(TM) for Health Care Staffing Services. The Joint Commission on Accreditation of Healthcare Organizations has awarded FMCEA the Health Care Staffing Services Certification for two years.

FMCEA met national standards addressing how staffing firms determine the qualifications and competency of their staff, how they place their staff, and the subsequent monitoring of the staff's performance.

The Joint Commission certification program was launched in October 2004 to offer an independent, comprehensive evaluation of a staffing firm's abilities to provide competent staffing services.

Dr. Paul Zabetakis, CEO of Fresenius Medical Care Extracorporeal Alliance commented, "We're very proud to receive the Joint Commission's Gold Seal of Approval. This certification recognizes FMCEA's dedication to providing hospitals with perfusionists, nurses, and technicians that are dedicated to safe, high-quality patient care".

Michele Sacco, executive director, Health Care Staffing Services Certification, Joint Commission commented: "Health care organizations that contract with FMCEA can look to this certification as an assurance that FMCEA demonstrates a commitment to providing and continuously improving quality services."

FMCEA provides a comprehensive suite of extracorporeal services including perfusion, autotransfusion, apheresis, and other immunoadsorption therapies to over 400 hospitals across the country. As the leader in cardiovascular perfusion, blood conservation, and therapeutic blood treatment services, FMCEA provides partner hospitals a specialized clinical staff with the highest level of skills, continuous leadership training, patient care, and the most current clinical training available.

Founded in 1951, the Joint Commission seeks to continuously improve the safety and quality of care provided to the public through the provision of health care accreditation and related services that support performance improvement in health care organizations. The Joint Commission evaluates and accredits more than 15,000 health care organizations and programs in the United States, including more than 8,200 hospitals and home care organizations, and more than 6,800 other health care organizations that provide long term care, assisted living, behavioral health care, laboratory and ambulatory care services. The Joint Commission also accredits health plans, integrated delivery networks, and other managed care entities. In addition, the Joint Commission provides certification of disease-specific care programs and primary stroke centers. An independent, not-for-profit organization, the Joint Commission is the nation's oldest and largest standards-setting and accrediting body in health care.

Fresenius Medical Care is the world's largest, integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,400,000 individuals worldwide. Through its network of approximately 2,000 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to approximately 157,000 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Source: Business Wire

More News in this Category